| Literature DB >> 30249320 |
Han-Wei Chu1, Binesh Unnikrishnan1, Anisha Anand1, Ju-Yi Mao1,2,3, Chih-Ching Huang1,4,5.
Abstract
Nanoparticle-assisted laser desorption/ionization mass spectrometry (LDI-MS) is a powerful tool for the analysis of a wide range of molecules. Many of the drawbacks in the matrix-assisted laser desorption/ionization mass spectrometry (MALDI-MS) can be avoided with the application of nanomaterials as matrices as well as substrates for the LDI-MS to achieve a low background noise in low m/z region and high reproducibility. Surface-assisted LDI (SALDI)-MS, especially the nanoparticle-based LDI-MS, has emerged as a promising technique for the analysis of trace amounts of substances in various biological samples due to their high surface area for analyte enrichment, efficient desorption/ionization, and homogeneous crystallization of sample. Therefore, it is highly useful in clinical, forensic, medical, food and drug analyses, disease diagnosis, and various other fields. In this review, we briefly discuss the application of various nanomaterials, which include metal-based, carbon-based, silicon-based nanomaterials and nanocomposites, as matrices and substrates for LDI-MS based drug and metabolite analyses and possible detection strategies. Also, we discuss the idea of using "mass tag" for signal amplification for drug and metabolite detection using nanoparticle assisted LDI-MS.Entities:
Keywords: Drugs; Laser desorption and ionization; Mass spectrometry; Matrix; Metabolites; Nanoparticles
Mesh:
Substances:
Year: 2018 PMID: 30249320 PMCID: PMC9298562 DOI: 10.1016/j.jfda.2018.07.001
Source DB: PubMed Journal: J Food Drug Anal Impact factor: 6.157
Fig. 1Schematic representation of a SALDI process mechanism.
Various types of nanomaterial substrates used for the detection of drugs or metabolites by LDI-MS.
| Category | Probe/substrate | Nanomaterial properties or LDI process | Analytes | LOD | References |
|---|---|---|---|---|---|
| Metal-based | Au nanoshell | plasmonic, generation of hot carriers conductive, nanostructured, and transparent | amino acids and carbohydrate | 3–30 pmol | [ |
| ITO | lipids, glycerol, and creatinine | 6 mg L−1 | [ | ||
| TiO2 nanowire | photoabsorption | benzylpenicillin | 0.4 ng mL−1 | [ | |
| TiO2 NPs | photoabsorption | 18 candidate metabolites from bacteria | n/a | [ | |
| HSA-Fe3O4 NPs | affinity towards analytes molecules | phenytoin, ibuprofen, camptothecin, warfarin | 5 μM | [ | |
| ZnO, TiO2, Fe2O3, CeO2 | small size and large surface area, strong UV absorption | amitriptyline hydrochloride, imipramine hydrochloride, nortriptyline hydrochloride, promazine hydrochloride | n/a | [ | |
| Au NPs, Ag NPs, Pd NPs, Pt NPs | photoabsorption, binding affinity, internal energy transfer | benzylpyridinium chloride | n/a | [ | |
| Au NPs | photoabsorption, high salt tolerance | progesterone, testosterone, cortisol, ribose, glucose, maltose, 5-HIAA, tryptophan, GM1, bradykinin, angiotensin I/II, substance P | 46.5–5115.7 nM | [ | |
| Au NPs | photoabsorption | palmitic acid, oleic acid, stearic acid, verapamil | n/a | [ | |
| Au NPs/KBr | photoabsorption | acetaminophen, noscapine, loratadine, coptisine, berberine, palmatine | n/a | [ | |
| ARRO SupraNano™ | photoabsorption | cocaine, methadone, aspirin, paracetamol, caffeine | n/a | [ | |
| TiO2-dopamine monolith | dopamine enhanced UV absorbance, selective binding of Lewis bases | fatty acids, cholesterols, ceramides, diacylglycerols, phosphatidylethanolamine, amino acids, alkaloids, peptides, lipids | n/a | [ | |
| Carbon-based | graphene, GO | photoabsorption, electron transport | scutellarin, wogonin, ferulic acid | n/a | [ |
| aptamer modified GO | enrichment, photoabsorption | cocaine, adenosine | n/a | [ | |
| graphite rods | photoabsorption | 9-phenylacridine | 0.1 pmol | [ | |
| C-Dots | mefenamic acid | 0.5 ng | [ | ||
| GO/MWCNT hybrid films | photoabsorption; functional groups of GO | cellobiose, leuenkephaline, glutamine, glucose, leucine, lysine, D-mannitol, phenylalanine | n/a | [ | |
| CNT, C60, PGC, G, HOPG, ND | phase transition | nenzylpyridinium halide derivatives | n/a | [ | |
| Graphene, GO, rGO | size dependent, photoabsorption | flavonoids, coumarin derivatives | 10 ppm | [ | |
| Graphene, GO | photoabsorption, electron transport | tetracycline | 2 nM | [ | |
| Graphite dots | strong UV absorption, hydroxyl groups provide high stability and favorable ΔG for analyte deprotonation | glucose, Ala-Gln, oligosaccharides; puerarin, daidzein, dihydrodaidzein | n/a | [ | |
| N-doped graphene | proton transfer, photoabsorbance process | fatty acid, peptide, epiandrosterone, testosterone, methyltestosterone, nilotinib | n/a | [ | |
| Silicon/Silica/Semiconductor | Nanostructured silicon | desorption ionization on porous silicon mass spectrometry imaging (DIOS-MSI) | methadone, heroine, EDDP | n/a | [ |
| Mesoporous germanium | photoabsorption | cocaine | 1.7–3.5 ng mL−1 | [ | |
| Silicon nanopillar arrays | photoabsorption | peptides, methadone | 32 ng mL−1 | [ | |
| Nanoporous GaN–Ag composite | high UV absorption | R6G, adenine | <50 pmoles | [ | |
| Silicon nanopost arrays | nanophotonic interaction | cAMP, acetylcholine, glucose, cholesterol, amino acids, small organic acids, phospholipids, fatty acids | n/a | [ | |
| Porous silicon | high UV absorption | methadone | 14.74–19.50 ng mL−1 | [ | |
| Nanostructured Silicon | nanostructure-initiator mass spectrometry (NIMS) | rapamycin, tigylglycine, N-acetyl-glutamic acid, uridine monophosphate, isobutyrylcarnitine, stearic acid, D-glucose | n/a | [ | |
| Ordered silicon nanocavity arrays | desorption ionization on porous silicon-mass spectrometry (DIOS-MS) | benzylpyridinium salts, DPPC, angiotensin III | n/a | [ | |
| Ordered silicon nanocavity arrays | desorption ionization on porous silicon-mass spectrometry (DIOS-MS) | methamphetamine, cocaine, MDMA | n/a | [ | |
| Nanoporous silicon microparticles | photoabsorption | methamphetamine, cocaine, MDMA, methadone, EDDP | ~20 ng mL−1 | [ | |
| hydrophobic silica powder | photoabsorption | nicotine | n/a | [ | |
| DHB + porous silicon | matrix-enhanced nanostructure initiator mass spectrometry (ME-NIMS) | pentamidine | 0.005 μM | [ | |
| Nanostructured Silicon | morphology-driven controlled nanostructure-initiator mass spectrometry (NIMS) | arginine, palmitylcarnitine, streptomycin, bradykinin, angiotensin, neurotensin | n/a | [ | |
| Nanoporous silicon films | perfluoro coating assisted desalting | taurine, aspartic acid, malic acid, glutamic acid, histidine | ~1 μM | [ | |
| Composite-based | PAN/Nafion®/CNT | photoabsorption | verapamil, methotrimeprazine, propranolol, chloroprothixene | 220 fM | [ |
| Au/PAA-GO film | photoabsorption, thermal conductivity | cellobiose, mannitol, glucose, leucine, phenylalanine, glutamine, leuenkephalin | n/a | [ | |
| SiO2@Ag particles | plasmonic resonance | mannitol, glucose | 100 ng μL−1 | [ | |
| Ag-DIOS | silver adduct assisted | bromoisatin, lipids, cholesterol | n/a | [ | |
| plasmonic gold chip | plasmon resonance, hot carrier production | amino acids, carbohydrates, metabolites | n/a | [ | |
| Mass tag | thiolalkane-Au NPs | thermal desorption of ligand | enrofloxacin, ciprofloxacin | 50 mg kg−1 | [ |
| Fib–Au NPs–MCEM | NP fragmentation | thrombin, anticoagulants | n/a | [ |
n/a: not available.
Fig. 2Schematic representation of Au NPs coated KBr pellet for SALDI-MS and FT-IR analysis of traditional Chinese medicine. (Reproduced with permission from Ref. [42]).
Fig. 3Schematic representation of enrichment and detection strategy for the analysis of phenytoin, ibuprofen, camptothecin, and warfarin in urine and serum samples using human serum albumin-modified Fe2O3 nanoparticles. (Reproduced with permission from Ref. [19]).
Fig. 4Schematic representation of SALDI-MS coupled with (A) thioalkane as amplification tag for detection of enrofloxacin and ciprofloxacin, and (B) gold cluster ions as amplification tag for monitoring of thrombin activity and anticoagulant screening. (Reproduced with permission from Refs. [7] and [47], respectively).
Fig. 5MSI of puerarin and its metabolites in rat kidney. (A) MALDI mass spectrum (negative-ion mode) of mouse serum after intraperitoneal administration of puerarin. Inset: Zoomed-in view of the spectrum in m/z 410–430, characteristic peak of puerarin: [M – H] at m/z 416. (B) Metabolic pathways showing puerarin and its two metabolites, (C) MALDI-MS images of the drug and its metabolites (puerarin, m/z: 416; daidzein, m/z: 253; and dihydrodaidzein, m/z: 255) in a kidney tissue slice with an optical micrograph of an H&E-stained consecutive slice as a reference. The color bar encodes the signal intensities of the three small molecules in MSI. Reproduced with permission from Ref. [52].
Fig. 6Schematic for (A) pSi-MP extraction of illicit drugs compounds from biological fluids, (B) pSi-MPs removed from the sample solution, (C) deposition onto standard MALDI target plate using double sided carbon tape and (D) analysis using SALDI-MS. (Reproduced with permission from Ref. [58]).
Fig. 7Workflow for biofluid analysis by silicon GLAD film. (A) Cleaving silicon GLAD film into workable wafers. (B) Modifying Si GLAD film with pFMe2SiCl solution to obtain a perfluoro coated surface with optimal contact angle. (C) Preparation of deproteinated human serum sample. (D) On-chip desalting and (E) mounting the SALDI chips on a custom MALDI plate for MS analysis. (Reproduced with permission from Ref. [63]).
Fig. 8Schematic representation of (A) work flow and (B) LDI-MS process using SiO2@Ag nanoshells as substrate for the detection of drugs and metabolites (Reproduced with permission from Ref. [65]).
Fig. 9(A) MALDI-MS spectrum using α-cyano-4-hydroxycinnamic acid as matrix and (B) SALDI-MS spectrum using polyacrylonitrile/Nafion®/carbon nanotube composite as substrate for the detection of verapamil (V), chlorprothixene (C), methotrimeprazine (M) and propranolol (P). (Reproduced with permission from Ref. [13]).